Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Geriatric MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy.Mov Disord. 2017; 32: 1264-1310
- Parkinson’s disease: the quintessential neuropsychiatric disorder.Mov Disord. 2011; 26: 1022-1031
- Prevalence of Parkinson’s disease across North America.NPJ Parkinsons Dis. 2018; 4: 21
- The relationship of Parkinson disease with aging.Arch Neurol. 2007; 64: 1242-1246
- Update on treatments of nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review.Mov Disord. 2019; 34: 180-198
- Clinical spectrum of impulse control disorders in Parkinson’s disease.Mov Disord. 2015; 30: 121-127
- Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group.Mov Disord. 2007; 22: 1061-1068
- The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria.Mov Disord. 2010; 25: 763-766
- Musical hallucinations: review of treatment effects.Front Psychol. 2015; 6: 814
- Visual plus nonvisual hallucinations in Parkinson’s disease: development and evolution over 10 years.Mov Disord. 2011; 26: 2196-2200
- Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis.Neurology. 2000; 55: 281-288
- The delusional misidentification syndromes: strange, fascinating, and instructive.Curr Psychiatry Rep. 2009; 11: 185-189
- Impact of standard of care for psychosis in Parkinson disease.J Neurol Neurosurg Psychiatry. 2008; 79: 1413-1415
- The anticholinergic risk scale and anticholinergic adverse effects in older persons.Arch Intern Med. 2008; 168: 508-513
- Dopamine agonist withdrawal syndrome in Parkinson disease.Arch Neurol. 2010; 67: 58-63
- Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease.N Engl J Med. 1999; 340: 757-763
- Clozapine in drug induced psychosis in Parkinson’s disease: a randomized, placebo controlled study with open follow up.J Neurol Neurosurg Psychiatry. 2004; 75: 689-695
- Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicenter, double-blind, placebo-controlled randomized trial.Lancet. 2010; 376: 1829-1837
- Exogenous melatonin for delirium prevention: a meta-analysis of randomized controlled trials.Mol Neurobiol. 2016; 53: 4046-4053
- Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase.Mov Disord. 2016; 31: 45-52
- A 12-year population-based study of psychosis in Parkinson disease.Arch Neurol. 2010; 67: 996-1001
- A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson’s disease patients without dementia.Parkinsonism Relat Disord. 2008; 14: 37-42
- What predicts mortality in Parkinson disease? A prospective population-based long-term study.Neurology. 2010; 75: 1270-1276
- Longitudinal outcome of Parkinson’s disease patients with psychosis.Neurology. 2003; 60: 1756-1761
- Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.Arch Neurol. 1999; 56: 595-601
- Psychiatric comorbidities in patients with Parkinson disease and psychosis.Neurology. 2004; 63: 293-300
- Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease.Mov Disord. 2005; 20: 1439-1448
- A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa.N Engl J Med. 2000; 342: 1484-1491
- Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease.Arch Neurol. 2009; 66: 563-570
- Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations.Neurology. 1998; 50: 515-517
- The scientific and clinical basis of the treatment of Parkinson disease.Neurology. 2009; 72: S1-S136
- Parkinson’s disease, visual hallucinations and apomorphine: a review of the available evidence.Parkinsonism Relat Disord. 2016; 27: 35-40
- Intravenous apomorphine therapy in Parkinson’s disease: clinical and pharmacokinetic observations.Brain. 2001; 124: 331-340
- Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease.Clin Neuropharmacol. 2002; 25: 107-110
- Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.N Engl J Med. 1993; 329: 162-167
- QTc prolongation with antipsychotics: is routine ECG monitoring recommended?.J Psychiatr Pract. 2014; 20: 196-206
- Clozapine in drug-induced psychosis in Parkinson’s disease.Lancet. 1999; 353: 2041-2042
- Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis.Arch Neurol. 2011; 68: 899-904
- Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.J Clin Psychiatry. 1998; 59: 3-7
- Clozapine in Parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action.Mov Disord Clin Pract. 2015; 3: 116-124
- Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease.Mov Disord. 2005; 20: 958-963
- Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration.Mov Disord. 2007; 22: 313-318
- A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease.Neuropsychiatr Dis Treat. 2009; 5: 327-332
- Pimavanserin for patients with Parkinson’s disease psychosis: a randomized, placebo-controlled phase 3 trial.Lancet. 2014; 383: 533-540
- Perspective on pimavanserin and the SASP-PD: novel scale development as a means to FDA approval.Am J Geriatr Psychiatry. 2018; 26: 1007-1011
- Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease.Mov Disord. 2000; 15: 201-211
- Association of antipsychotic use with mortality risk in patients with Parkinson disease.JAMA Neurol. 2016; 73: 535-541
- Medication-related impulse control and repetitive behaviors in Parkinson disease.Arch Neurol. 2007; 64: 1089-1096
- Screening for impulse control disorder symptoms in patients with de novo Parkinson disease: a case-control study.Neurology. 2013; 80: 176-180
- Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.Arch Neurol. 2010; 67: 589-595
- Longitudinal analysis of impulse control disorders in Parkinson disease.Neurology. 2018; 91: e189-e201
- Impulse control disorders in advanced Parkinson’s disease with dyskinesia: the ALTHEA study.Mov Disord. 2017; 32: 1557-1565
- Patient versus informant reporting ICD symptoms in Parkinson’s disease using the QUIP: validity and variability.Parkinsonism Relat Disord. 2011; 17: 153-155
- A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists.Eur J Neurol. 2016; 23: 1255-1261
- Prospective cohort study of impulse control disorders in Parkinson’s disease.Mov Disord. 2013; 28: 327-333
- Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.Sleep. 2010; 33: 81-87
- Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study.Ann Neurol. 2010; 68: 963-968
- Impulse control disorders in Parkinson’s disease: a cohort of 35 patients.Rev Neurol (Paris). 2012; 168: 143-151
- Impulse control disorders in Parkinson disease: a multicenter case-control study.Ann Neurol. 2011; 69: 986-996
- Punding prevalence in Parkinson’s disease.Mov Disord. 2007; 22: 1179-1181
- Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome.Mov Disord. 2004; 19: 397-405
- Dopamine dysregulation syndrome in Parkinson’s disease: from clinical and neuropsychological characterization to management and long-term outcome.J Neurol Neurosurg Psychiatry. 2014; 85: 311-318
- Long-term follow-up of impulse control disorders in Parkinson’s disease.Mov Disord. 2008; 23: 75-80
- EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease.Mov Disord. 2015; 30: 510-516
- Pathological gambling in Parkinson disease is reduced by amantadine.Ann Neurol. 2010; 68: 400-404
Article info
Publication history
Published online: October 17, 2019
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
